检验

订阅

MedSci主页 / 所有栏目 / 检验

INT J LAB HEMATOL：用于检测FVIII抑制剂的新型自动筛选方法

2017-04-14 MedSci MedSci原创

自动化检测
关注

VIII因子活性通常是通过测量患者血浆样品的活化部分凝血活酶时间（aPTT）并从标准曲线确定活性百分比来定义的。为了最大限度地检测凝血因子抑制剂，应该对患者曲线与标准曲线相比平行度进行主观评估。研究人员开发并验证了一种自动化的客观方法，以评估用于在常规FVIII测定过程中抑制剂快速筛选工具的平行结果如何。

近日，国际杂志INT J LAB HEMATOL上在线发表一篇关于用于开发检测FVIII抑制剂的新型自动筛选方法的研究。

VIII因子活性通常是通过测量患者血浆样品的活化部分凝血活酶时间（aPTT）并从标准曲线确定活性百分比来定义的。为了最大限度地检测凝血因子抑制剂，应该对患者曲线与标准曲线相比平行度进行主观评估。研究人员开发并验证了一种自动化的客观方法，以评估用于在常规FVIII测定过程中抑制剂快速筛选工具的平行结果如何。

研究人员对FVIII缺陷患者（有无抑制剂的血友病）进行FVIII测定。利用独立的Microsoft Excel程序获得平行度曲线斜率与正常标准曲线的比值，并确定预测抑制剂存在的临界值比率。

对病人FVIII抑制剂检测的对照斜率<0.45的临界值比率为100％，特异性为91.6％，阳性预测值为92.3％，阴性预测值为100％。

利用有无抑制剂的患者的平行度曲线的斜率的比率，研究人员开发并验证了快速、自动化和客观的方法。并且用它来评估作为在常规FVIII测定期间检测因子的添加额外工具平行性。这种简单的自动化方法具有检测其它凝血因子抑制剂的潜力。

原始出处：

M. S. Evans, K. J. Donaldson and M. E. Eyster. Development of a novel automated screening method for detection of FVIII Inhibitors (pages 185–190) Version of Record online: 30 JAN 2017 | DOI: 10.1111/ijlh.12601

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1851412, encodeId=2ec71851412ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 30 23:45:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715778, encodeId=528d1e157787a, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=487e32047562, createdName=wjcjjian, createdTime=Sun Oct 15 23:45:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915944, encodeId=4dd41915944ca, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 14 07:45:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317270, encodeId=5474131e27017, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584370, encodeId=d4b615843e0d6, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-12-30 jklm09

    #抑制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1851412, encodeId=2ec71851412ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 30 23:45:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715778, encodeId=528d1e157787a, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=487e32047562, createdName=wjcjjian, createdTime=Sun Oct 15 23:45:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915944, encodeId=4dd41915944ca, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 14 07:45:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317270, encodeId=5474131e27017, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584370, encodeId=d4b615843e0d6, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-10-15 wjcjjian

    #FVIII#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1851412, encodeId=2ec71851412ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 30 23:45:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715778, encodeId=528d1e157787a, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=487e32047562, createdName=wjcjjian, createdTime=Sun Oct 15 23:45:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915944, encodeId=4dd41915944ca, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 14 07:45:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317270, encodeId=5474131e27017, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584370, encodeId=d4b615843e0d6, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-06-14 智智灵药

    #III#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1851412, encodeId=2ec71851412ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 30 23:45:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715778, encodeId=528d1e157787a, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=487e32047562, createdName=wjcjjian, createdTime=Sun Oct 15 23:45:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915944, encodeId=4dd41915944ca, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 14 07:45:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317270, encodeId=5474131e27017, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584370, encodeId=d4b615843e0d6, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-04-16 fengyi812

    #EMA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1851412, encodeId=2ec71851412ad, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Dec 30 23:45:00 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1715778, encodeId=528d1e157787a, content=<a href='/topic/show?id=b9bbe73853' target=_blank style='color:#2F92EE;'>#FVIII#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7738, encryptionId=b9bbe73853, topicName=FVIII)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=487e32047562, createdName=wjcjjian, createdTime=Sun Oct 15 23:45:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915944, encodeId=4dd41915944ca, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 14 07:45:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317270, encodeId=5474131e27017, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584370, encodeId=d4b615843e0d6, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Apr 16 03:45:00 CST 2017, time=2017-04-16, status=1, ipAttribution=)]
    2017-04-16 ms6747015003810650

    #筛选#

    0